Last reviewed · How we verify
human menopausal gonadotropin
Human menopausal gonadotropin (hMG) is a hormone preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and maturation in women undergoing fertility treatment.
Human menopausal gonadotropin (hMG) is a hormone preparation containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and maturation in women undergoing fertility treatment. Used for Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF), Anovulation and ovulatory disorders in women seeking pregnancy.
At a glance
| Generic name | human menopausal gonadotropin |
|---|---|
| Also known as | menopur, meriofert, Merional, Human Menopausal Gonadotropin(hMG), hMG |
| Sponsor | IVI Madrid |
| Drug class | Gonadotropin |
| Target | FSH receptor (FSHR) and LH receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
hMG is extracted from the urine of postmenopausal women and contains both FSH and LH in a 1:1 ratio. FSH directly stimulates follicle growth and estrogen production, while LH supports follicle maturation and triggers ovulation. This combination mimics the natural hormonal environment needed for controlled ovarian hyperstimulation in assisted reproductive technology.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)
- Anovulation and ovulatory disorders in women seeking pregnancy
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Abdominal pain or bloating
- Nausea
- Injection site reactions
- Mood changes
Key clinical trials
- The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles (PHASE4)
- Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer. (PHASE3)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome (PHASE2)
- Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (PHASE3)
- DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT (NA)
- Retrospective Study of High Dose Follitropin Delta in a Mixed Protocol With Human Chorionic Gonadotropin
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- human menopausal gonadotropin CI brief — competitive landscape report
- human menopausal gonadotropin updates RSS · CI watch RSS
- IVI Madrid portfolio CI